Association of TNF and FcÎ³RÎ™Î™Î™A gene polymorphisms with differential response to infliximab in a Greek cohort of Crohn's disease patients
AbstractBackground and Aim Infliximab (IFX) has revolutionized the treatment of patients with Crohn's disease (CD). However, a significant proportion of patients may fail to respond primarily or lose response over time. The genetic background of a particular individual may partially explain differences in responsiveness to anti-TNFÎ± therapy. The aim of this study was to investigate whether polymorphisms in the promoter region of the TNF and FcÎ³RÎ™Î™Î™A gene are associated with response to IFX in patients with CD.
Methods We investigated the following single nucleotide polymorphisms in the promoter region of the TNF gene (-238 G/A, -308 G/A, and -857 C/T) and the -158 V/F polymorphism in the FcÎ³RÎ™Î™Î™A gene in a cohort of 79 adults and 27 children, who were all Greek patients with CD. These polymorphisms were determined using PCR-RFLP or allele-specific PCR.
Results Regarding the 106 patients included in the study, 68 (64.15%) were classified as complete and 25 (23.58%) as partial responders to IFX, while 13 (12.26%) patients were primary non responders. There were no significant differences in the frequencies of the various TNF and FcÎ³RÎ™Î™Î™A genotypes among complete, partial responders or primary non responders.
Conclusion These results suggest that TNF and FcÎ³RÎ™Î™Î™A genotypes did not affect the response to IFX in this cohort of Greek patients with CD.
Keywords infliximab, Crohn's disease, promoter TNF gene, FcÎ³RÎ™Î™Î™A polymorphisms
Ann Gastroenterol 2011; 24 (1): 35-40